vs
Side-by-side financial comparison of Millrose Properties, Inc. (MRP) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Millrose Properties, Inc. is the larger business by last-quarter revenue ($194.9M vs $103.7M, roughly 1.9× Twist Bioscience Corp). Millrose Properties, Inc. runs the higher net margin — 63.0% vs -29.4%, a 92.5% gap on every dollar of revenue. On growth, Millrose Properties, Inc. posted the faster year-over-year revenue change (135.7% vs 16.9%).
Millrose Properties, Inc. is a U.S.-based real estate enterprise primarily focused on the acquisition, ownership, operation, and management of income-generating multi-family residential assets. Its core markets span the U.S. Mid-Atlantic and Southeast regions, and it also offers professional property management services to select third-party property owners.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
MRP vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $194.9M | $103.7M |
| Net Profit | $122.9M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 85.2% | -31.7% |
| Net Margin | 63.0% | -29.4% |
| Revenue YoY | 135.7% | 16.9% |
| Net Profit YoY | 208.7% | 3.4% |
| EPS (diluted) | $0.74 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $194.9M | — | ||
| Q4 25 | $189.5M | $103.7M | ||
| Q3 25 | $179.3M | — | ||
| Q2 25 | $149.0M | — | ||
| Q1 25 | $82.7M | — |
| Q1 26 | $122.9M | — | ||
| Q4 25 | $122.2M | $-30.5M | ||
| Q3 25 | $105.1M | — | ||
| Q2 25 | $112.8M | — | ||
| Q1 25 | $39.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q1 26 | 85.2% | — | ||
| Q4 25 | 84.8% | -31.7% | ||
| Q3 25 | 85.3% | — | ||
| Q2 25 | 85.1% | — | ||
| Q1 25 | 55.2% | — |
| Q1 26 | 63.0% | — | ||
| Q4 25 | 64.5% | -29.4% | ||
| Q3 25 | 58.6% | — | ||
| Q2 25 | 75.7% | — | ||
| Q1 25 | 48.1% | — |
| Q1 26 | $0.74 | — | ||
| Q4 25 | $0.74 | $-0.50 | ||
| Q3 25 | $0.63 | — | ||
| Q2 25 | $0.68 | — | ||
| Q1 25 | $0.39 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.9B | $456.1M |
| Total Assets | $9.6B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.0M | $197.9M | ||
| Q3 25 | $242.6M | — | ||
| Q2 25 | $66.6M | — | ||
| Q1 25 | $89.5M | — |
| Q1 26 | $5.9B | — | ||
| Q4 25 | $5.9B | $456.1M | ||
| Q3 25 | $5.9B | — | ||
| Q2 25 | $5.9B | — | ||
| Q1 25 | $5.9B | — |
| Q1 26 | $9.6B | — | ||
| Q4 25 | $9.3B | $638.1M | ||
| Q3 25 | $9.0B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | $-24.8M | ||
| Q3 25 | $123.1M | — | ||
| Q2 25 | $109.1M | — | ||
| Q1 25 | $21.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 30.05× | — | ||
| Q3 25 | 1.17× | — | ||
| Q2 25 | 0.97× | — | ||
| Q1 25 | 0.53× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRP
| Option fee revenues | $185.3M | 95% |
| Development loan income | $9.6M | 5% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
